Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||TP53 loss|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02612285||Phase II||SNX-5422||Study of SNX-5422 in TP53 Null Cancers||Terminated||USA||0|
|NCT04388852||Phase I||DS-3201b + Ipilimumab||DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers||Recruiting||USA||0|
|NCT04592237||Phase II||Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib||Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer||Recruiting||USA||0|